Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to 0.3%.

  • Entrada Therapeutics' Return on Capital Employed fell 4100.0% to 0.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.3%, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of 0.1% for FY2024, which is 1200.0% up from last year.
  • Entrada Therapeutics' Return on Capital Employed amounted to 0.3% in Q3 2025, which was down 4100.0% from 0.21% recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Return on Capital Employed registered a high of 0.2% during Q2 2024, and its lowest value of 0.4% during Q4 2022.
  • In the last 4 years, Entrada Therapeutics' Return on Capital Employed had a median value of 0.06% in 2023 and averaged 0.09%.
  • As far as peak fluctuations go, Entrada Therapeutics' Return on Capital Employed surged by 4500bps in 2024, and later crashed by -4200bps in 2025.
  • Entrada Therapeutics' Return on Capital Employed (Quarter) stood at 0.4% in 2022, then soared by 98bps to 0.01% in 2023, then surged by 1045bps to 0.09% in 2024, then tumbled by -418bps to 0.3% in 2025.
  • Its Return on Capital Employed stands at 0.3% for Q3 2025, versus 0.21% for Q2 2025 and 0.01% for Q1 2025.